CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B Therapy
Irving Jair Lara-Navarro, Luis Felipe Jave-Suárez, Juan Antonio Marchal, Ana Rebeca Jaloma-Cruz, Eleni Gavriilaki · 2024
Read CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B Therapy by Irving Jair Lara-Navarro, Luis Felipe Jave-Suárez, Juan Antonio Marchal, Ana Rebeca Jaloma-Cruz, Eleni Gavriilaki (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11676118.txt.
Description
Irving Jair Lara-Navarro and co-authors describe lab work from 2024 on gene editing as a route to treat hemophilia B. People with the illness lack a blood factor that helps clots form. Shots of the factor wear off fast, so a lasting fix would help.
The team used CRISPR/Cas9 to place a healthy copy of the F9 gene into human stem cells and into a test cell line. Both kinds of cells then made the missing factor, the authors report, though the stem cells took the edit less often. A virus-based test system helped check that the method worked. Next steps focus on raising how often the stem cells accept the edit.
Catalog record
| CREATOR | Irving Jair Lara-Navarro, Luis Felipe Jave-Suárez, Juan Antonio Marchal, Ana Rebeca Jaloma-Cruz, Eleni Gavriilaki |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |